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THE ABILITY of a series of human lung
carcinoma xenografts to predict clinical
response to cytotoxic drugs was demon-
strated by Shorthouse et al. (1980) when
tumour biopsy samples from patients with
lung cancer were established as xenografts
in immune-suppressed mice and the drug
combinations used to treat the patients
were also administered to the xenograft-
bearing mice. Tumour-growth delay in the
xenografts correlated closely with the
clinical tumour response in the patients.
That study suggested that these lung
tumour xenografts might be useful in
comparing the efficacy of new drug ana-
logues with the parent drugs. Vindesine is
a new Vinca alkaloid, derived from vin-
blastine and closely related to vincristine.
Phase II clinical trials suggest that
vindesine has activity against small-cell
and adenocarcinoma of the lung (Natale
et al., 1980; Mattson et al., 1980). Its
clinical efficacy has not been compared
with that of vincristine, however. The
anti-tumour effect of vindesine was there-
fore compared with vincristine in 4 lung-
carcinoma xenografts.
Female CBA/lac mice were immune-
suppressed by neonatal thymectomy, fol-
lowed 2-4 weeks later by 9 Gy whole-body
irradiation (Steel et al., 1978).
The 4 xenograft lines used in these
experiments were in early passage (6-12)
and had originally been established from
human material obtained at biopsy:
small-cell xenograft I from a peural
metastasis and the other 3 from skin
metastases. For each xenograft line,
tumour fragments were bilaterally im-
planted s.c. into the flanks of 8-10-week-
old mice, prepared as described above.
When the tumours had reached a vol-
ume of 0 3-0'5 cm3 they were ranked
according to their volume, calculated by
the formula TLD2/6, where L is the
longest diameter and D is the diameter at
right angles to it (Cobb & Mitchley, 1974)
and allocated to treatment or control
groups. Each group contained about 12
tumours of similar volume to those in the
other groups. Histology and chromosome
analysis, performed on each xenograft
line, confirmed their human origin.
Drugs were made up in normal saline,
and groups of mice were then treated with
a single i.p. bolus injection of vincristine
sulphate (Oncovin-Eli Lilly) at a dose of
1 2 mg/kg or vindesine sulphate (Eldisine
-Eli Lilly) at a dose of 3 0 mg/kg. Due to
their known different toxicities (vincris-
tine neurotoxicity; vindesine marrow and
neurotoxicity) overall survival rather than
target-tissue toxicity was used in assessing
equitoxic doses.
The parameter of chemotherapeutic
response was the in situ endpoint of
growth delay (GD) which was determined
by dividing the difference between mean
doubling times of control (TD,) and
treated tumours (TDt) by TD,
GD=TDt-TDc TD-
This produced an estimate ofgrowth delay
in terms of TDC, equivalent to the
doubling times saved (DTS) of Kopper &
Steel (1975).
The actual growth rates were calculatedVINDESINE AND VINCRISTINE IN LUNG CANCER
by comparing the tumour volume ofevery
tumour at time t (Vt) with its own volume
at the beginning of the experiment (Vo).
The ratio Vt:Vo was then calculated for
each tumour at each sampling time, and a
mean and standard error were calculated
for each treatment group at each samp-
ling time.
In the one case where a tumour went
into complete remission (i.e. the tumour
disappeared and did not regrow by the end
of the experiment) the tumour was
excluded from all subsequent growth-
delay estimations.
The Mann-Whitney U test was used to
perform the statistical analysis. The
doubling times of the individual tumours
for each group were compared with those
of the other groups.
The mortalities produced by the 2
agents in this experiment were very
similar: 7/31 mice treated with vindesine
and 6/29 mice treated with vincristine
died before the end of the experiment.
This showed that the ratio of vindesine:
vincristine used clinically (5:2) produced
equal mortality rates when administered
by i.p. injection to immune-suppressed
mice.
Comparative tumour growth delays for
vindesine and vincristine are given in the
Table. For both small-cell carcinoma
TABLE.-Growth delays produced by vinde-
sine (3.0 mg/kg) or vincristine (1.2mg/kg
Tumour
Small-cell I
Small-cell II
Adenocarcinoma I
Adenocarcinoma II
Vindesine
2-2
2-6
2-3
0 4
Vincristine
1.0
1.0
1 6
0.0
p
<0-02
0 007
NS
NS
xenografts vindesine was significantly
more effective than vincristine (Figs 1 &
2). Vindesine also produced one complete
remission in small-cell xenograft II. No
significant difference was found between
the 2 agents for either of the adenocarci-
noma xenografts (Figs 3 & 4).
Tumour growth-delay studies are no
substitute for clinical trials. Nevertheless,
they might indicate priorities for new drug
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FiG. 1.-Responses of human small-cell xeno-
graft I to vindesine and vincristine. (The
tumour volume at a particular day, Vt, is
expressed as a ratio of the tumour volume
at the start of the experiment, Vo.) Tum-
ours treated on Day 2. A, Untreated
tumours. 0, Vincristine 1-2 mg/kg. *,
Vindesine 3-0 mg/kg. Vertical lines indicate
+ 1 s.e.
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FIG. 2.-Responses of human small-cell
xenograft II to vindesine and vincristine.
(Tumours treated on Day 2). Symbols as in
Fig. 1.
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FIG. 3.-Responses ofhumanadenocarcinoma Days
xenograft I to vindesine and vincristine. FIG. 4.-Responses ofhumanadenocarcinoma
(Tumours treated on Day 2). Symbols as xenograft II to vindesine and vincristine.
in Fig. 1. (Tumours treated on Day 2.) Symbols as
in Fig. 1.
studies in the clinic. These results suggest
that vindesine might be worth comparing
with the parent compound vincristine in
combination chemotherapy for small-cell
lung cancer. Similar xenograft studies
might also be used for the preclinical
assessment of other new agents and
analogues.
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